Key result
Intravenous hAD-MSCs improve neurological recovery and reduce vascular remodeling in hyperglycemic stroke rats.
Answers are grounded in this paper and cite their sources.
BACKGROUND: Over 50% of acute stroke patients have hyperglycemia, which is associated with a poorer prognosis and outcome. Our aim was to investigate the impact of hyperglycemia on behavioral recovery and brain repair of delivered human adipose tissue-derived mesenchymal stem cells (hAD-MSCs) in a rat model of permanent middle cerebral artery occlusion (pMCAO). METHODS: hAD-MSCs or saline were intravenously administered. We evaluated behavioral outcome, infarct size by MRI, and brain plasticity markers by immunohistochemistry (glial fibrillary acidic protein [GFAP], Iba-1, synaptophysin, doublecortin, CD-31, collagen-IV, and α-smooth muscle actin [α-SMA]). RESULTS: The hyperglycemic group exhibited more severe neurological deficits; lesion size and diffusion coefficient were larger compared with the non-hyperglycemic rats. GFAP, Iba-1, and α-SMA were increased in the hyperglycemic group. The hyperglycemic rats administered hAD-MSCs at 48 h after pMCAO had improved neurological impairment. Although T2-MRI did not show differences in lesion size between groups, the rADC values were lower in the treated group. Finally, the levels of GFAP, Iba-1, and arterial wall thickness were lower in the treated hyperglycemic group than in the nontreated hyperglycemic group at 6 weeks post-stroke. CONCLUSIONS: Our data suggest that rats with hyperglycemic ischemic stroke exhibit increased lesion size and impaired brain repair processes, which lead to impairments in behavioral recovery after pMCAO. More importantly, hAD-MSC administration induced better anatomical tissue preservation, associated with a good behavioral outcome.
No takes yet. Share an insight, caveat, or question.
Frutos et al. (2019) studied Hyperglycemic ischemic stroke (rat model of permanent middle cerebral artery occlusion). Intravenous human adipose tissue-derived mesenchymal stem cells (hAD-MSCs) vs. Saline was evaluated on Behavioral outcome, infarct size by MRI, and brain plasticity markers by immunohistochemistry. Intravenous hAD-MSCs given 48 h post-stroke improved neurological recovery and reduced rADC values, GFAP, Iba-1, and arterial wall thickness at 6 weeks in hyperglycemic stroke rats.
Synapse has enriched 10 related papers. Consider them for comparative context: